News
PFE
26.03
+1.28%
0.33
Eli Lilly, Pfizer, Johnson secure spots on China’s drug catalog, Bloomberg says
TipRanks · 4h ago
Pfizer presents results from the Phase 3 BASIS study on HYMPAVZI
TipRanks · 5h ago
Trump signs memo to align U.S. vaccines for children with practices from other countries
Seeking Alpha · 1d ago
Lennar, Pfizer, Cloudflare, Symbotic, Workday: Trending by Analysts
TipRanks · 1d ago
Do These 3 Healthcare Stocks Need a Checkup?
NASDAQ · 2d ago
Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
TipRanks · 2d ago
Mixed options sentiment in Pfizer with shares up 1.15%
TipRanks · 2d ago
Is This Pharmaceutical Giant a Buy After a Major Acquisition?
NASDAQ · 2d ago
2 Headwinds Facing Pfizer Stock Going Into 2026
The Motley Fool · 2d ago
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
NASDAQ · 2d ago
Pfizer: The Market Is Still Wrong About It
Seeking Alpha · 2d ago
Does Pfizer’s Post Pandemic Strategy Make Sense at Today’s Price?
Simply Wall St · 2d ago
3 Low-Volatility Stocks with Warning Signs
Barchart · 2d ago
Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
TipRanks · 3d ago
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
Seeking Alpha · 3d ago
FDA shift in drug study requirements sends trial runners lower
TipRanks · 3d ago
FDA to reduce number of trials required for drug approvals, STAT reports
TipRanks · 3d ago
Does PADCEV Keytruda Bladder Cancer Win Reshape The Bull Case For Pfizer (PFE)?
Simply Wall St · 3d ago
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Seeking Alpha · 3d ago
Former FDA commissioners castigate plan to change vaccine approval standards
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.